| Authors: |
Dumarey M; Global Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Gothenburg, Sweden. melanie.dumarey@astrazeneca.com., Carducci TM; Analytical Commercialization Technology, Merck & Co., Inc., 126 E. Lincoln Ave, Rahway, NJ, 07065, United States of America., Walworth MJ; Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America., Smith CJ; Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America., García-Muñoz S; Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America., Nielsen S; Janssen Supply Chain, Johnson & Johnson, New Brunswick, NJ, United States of America., Jacquart S; Janssen Pharmaceutica NV, Beerse, Belgium., da Silva AT; Janssen Pharmaceutica NV, Beerse, Belgium., Altan S; Manufacturing and Applied Statistics, Janssen Pharmaceutical R&D LLD, Raritan, NJ, 08869, United States of America., Otava M; Manufacturing and Applied Statistics, Janssen-Cilag S.R.O., Prague, Czechia., Lan Y; Analytical Development, Pharmaceutical Sciences, Takeda, Cambridge, MA, 02139, United States of America., Zaborenko N; Synthetic Molecule Design and Development, Eli Lilly and Company, Indianapolis, IN, 46285, United States of America. |
